| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Gamma-secretase modulator 3 targets gamma-secretase, a multi-subunit protease complex responsible for the cleavage of amyloid precursor protein (APP). Unlike gamma-secretase inhibitors that completely block enzyme activity, modulators alter the cleavage site specificity to reduce production of the pathogenic Abeta42 peptide while maintaining overall enzyme function. This approach aims to preserve the physiological functions of gamma-secretase while lowering amyloidogenic Abeta species.
|
|---|---|
| ln Vitro |
In vitro, gamma-secretase modulator 3 reduces Abeta production in cell-based assays. The compound modulates gamma-secretase activity to shift the cleavage pattern of APP, resulting in decreased levels of Abeta42 peptide. Detailed IC₅0 values and specific potency data are not extensively documented in the available literature. The compound's activity is typically evaluated using cell lines expressing APP or by measuring secreted Abeta peptide levels via ELISA or mass spectrometry.
|
| ln Vivo |
In vivo activity data for gamma-secretase modulator 3 are not well characterized in the public domain. As a gamma-secretase modulator, the compound is expected to reduce brain Abeta42 levels in animal models of Alzheimer's disease. Typical in vivo studies would involve oral or intraperitoneal administration in transgenic mouse models (such as APP/PS1 mice), followed by measurement of brain and cerebrospinal fluid Abeta peptide levels. Further studies are needed to confirm in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
The in vitro enzyme assay for gamma-secretase modulators typically uses purified gamma-secretase enzyme complex or membrane fractions containing the enzyme. The substrate (usually a recombinant APP fragment or synthetic peptide) is incubated with the enzyme in the presence of varying concentrations of the modulator. Cleavage products are analyzed by mass spectrometry or ELISA to determine the ratio of Abeta42 to total Abeta. The assay measures the shift in cleavage site specificity rather than complete enzyme inhibition.
|
| Cell Assay |
For in vitro cell-based assays, cells expressing APP (such as CHO cells or neuroblastoma cell lines) are cultured and treated with gamma-secretase modulator 3 at various concentrations. After incubation for 24-48 hours, conditioned media is collected and Abeta peptide levels (Abeta40 and Abeta42) are measured by ELISA or immunoassay. The ratio of Abeta42 to Abeta40 is calculated to determine the modulatory effect. Cytotoxicity is assessed using standard viability assays.
|
| Animal Protocol |
In vivo animal studies for gamma-secretase modulators typically involve transgenic mouse models of Alzheimer's disease (such as APP/PS1 or Tg2576 mice). The compound is administered orally or intraperitoneally at various doses for a defined treatment period. Brain tissue and cerebrospinal fluid are collected at study termination for Abeta peptide quantification by ELISA or mass spectrometry. Behavioral testing may also be performed to assess cognitive effects. Pharmacodynamic markers of target engagement are evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of gamma-secretase modulator 3 are not extensively documented. The compound has molecular weight 434.53 and molecular formula C24H23FN4OS. Solubility is limited in aqueous media (approximately 1.0×10-3 g/L at 25degC). The compound is soluble in DMSO at <1 mg/mL. For in vivo formulations, standard approaches using DMSO, Tween 80, and saline (10:5:85 ratio) may be employed. Storage recommendations include -20degC for powder (3 years) and -80degC for solutions (6 months).
|
| Toxicity/Toxicokinetics |
Toxicological data for gamma-secretase modulator 3 are not well characterized. As a research chemical, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications. Gamma-secretase modulators are generally considered to have a better safety profile than gamma-secretase inhibitors due to preservation of Notch signaling. Comprehensive toxicity profiling would be required for therapeutic development.
|
| Additional Infomation |
Gamma-secretase modulator 3 (CAS# 1431697-84-5) is a research compound used in Alzheimer's disease research. It is also known as gamma-secretase modulator 3 with IUPAC name 4-(4-fluorophenyl)-N-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine. The compound is not approved for clinical use and is strictly for laboratory research purposes. Further studies are needed to fully characterize its pharmacological profile.
|
| Molecular Formula |
C24H23FN4OS
|
|---|---|
| Molecular Weight |
434.5290
|
| Exact Mass |
434.157
|
| CAS # |
1431697-84-5
|
| PubChem CID |
71576689
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
615.5±65.0 °C at 760 mmHg
|
| Flash Point |
326.0±34.3 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.681
|
| LogP |
6.86
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
592
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CN(C=N1)C2=C(C=C(C=C2)NC3=NC4=C(S3)CCCC4C5=CC=C(C=C5)F)OC
|
| InChi Key |
UCGDOBMXNQTSSO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H23FN4OS/c1-15-13-29(14-26-15)20-11-10-18(12-21(20)30-2)27-24-28-23-19(4-3-5-22(23)31-24)16-6-8-17(25)9-7-16/h6-14,19H,3-5H2,1-2H3,(H,27,28)
|
| Chemical Name |
4-(4-fluorophenyl)-N-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :< 1 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3013 mL | 11.5067 mL | 23.0134 mL | |
| 5 mM | 0.4603 mL | 2.3013 mL | 4.6027 mL | |
| 10 mM | 0.2301 mL | 1.1507 mL | 2.3013 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
